Alzheimer’S Disease Dementia

Clonal hematopoiesis of indeterminate potential, which has been shown to substantially increase risk for blood cancer and cardiovascular disease, also appeared associated with protection from Alzheimer’s disease, according to study results.

In a systematic review and meta-analysis of 95 studies, researchers identified a global, age-standardized rate of young-onset dementia of 119 per 100,000 population, which is higher than previous estimates.

Aduhelm demonstrated a consistent treatment effect for slowing decline in cognitive, functional and behavioral domains among patients with early Alzheimer’s disease in item-level analysis of the phase 3 EMERGE study.

Individuals with a “cognitively active lifestyle” delayed dementia onset up to 5 years compared with individuals who engaged in low levels of cognitive activity, according to findings from a longitudinal cohort study published in Neurology.

The FDA called for a federal investigation into the approval of Aduhelm for the treatment of patients with Alzheimer’s disease, as reported by STAT.

Multimodal neuroimaging showed varying relationships between indices of obesity and the brain at three different diagnostic stages, including cognitively healthy, mild cognitive impairment and Alzheimer’s disease dementia.

Noncommunicable neurological disorders resulted in “a large and increasing burden” in the United States, according to a systematic analysis of the Global Burden of Disease study from 2017 that was published in JAMA Neurology.

In the general population, both high and low levels of hemoglobin were linked to a greater long-term risk for dementia, including Alzheimer’s disease, data published in Neurology showed.

In this week’s edition, anxiety, depression worse among older men with vision impairment; emerging therapeutics may improve outcomes in pediatric patients with rare disorders; glioblastoma presents roadblock to successful immunotherapy; and more.